why choose us

First received: January 17, 2023

Clinical Trial: A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

Study Status: Completed

Recruit Status: Completed

Condition: Retinopathy of Prematurity

Study Type: Interventional


Official Title: A Dosing Study of Two Different Doses (0.3125mg Versus 0.625mg) Intravitreal Bevacizumab for Type 1 ROP (Retinopathy of Prematurity)

Brief Summary: The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding :Serum Systemic VEGF levels. Retinal Vascularization.

Read more